{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T20:02:35Z","timestamp":1784491355623,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,19]]},"DOI":"10.7759\/cureus.112962","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T19:54:57Z","timestamp":1784490897000},"source":"Crossref","is-referenced-by-count":0,"title":["Fabry Disease Diagnosed With Lung Nodule: A Unique Presentation in a Young Female Patient"],"prefix":"10.7759","author":[{"given":"Joseph","family":"Joppich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanth","family":"Mandavilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rojas Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain DP","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010, 5:30. 10.1186\/1750-1172-5-30","journal-title":"Orphanet J Rare Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.66.S1.10","article-title":"Fabry disease: genetics, pathology, and treatment","volume":"66Suppl 1","author":"Bernardes TP","year":"2020","unstructured":"Bernardes TP, Foresto RD, Kirsztajn GM. Fabry disease: genetics, pathology, and treatment. Rev Assoc Med Bras (1992). 2020, 66Suppl 1:s10-6. 10.1590\/1806-9282.66.S1.10","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta A","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, et al.. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004, 34:236-42. 10.1111\/j.1365-2362.2004.01309.x","journal-title":"Eur J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease","volume":"101","author":"Germain DP","year":"2022","unstructured":"Germain DP, Levade T, Hachulla E, et al.. Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease. Clin Genet. 2022, 101:390-402. 10.1111\/cge.14102","journal-title":"Clin Genet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147663","article-title":"X chromosome inactivation in carriers of Fabry disease: Review and meta-analysis","volume":"22","author":"Viggiano E","year":"2021","unstructured":"Viggiano E, Politano L. X chromosome inactivation in carriers of Fabry disease: Review and meta-analysis. Int J Mol Sci. 2021, 22:7663. 10.3390\/ijms22147663","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-21","article-title":"Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring","volume":"4","author":"Hoffmann B","year":"2009","unstructured":"Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009, 4:21. 10.1186\/1750-1172-4-21","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1023\/a:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra C","year":"2001","unstructured":"Whybra C, Kampmann C, Willers I, et al.. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis. 2001, 24:715-24. 10.1023\/a:1012993305223","journal-title":"J Inherit Metab Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria L","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, et al.. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016, 89:44-54. 10.1111\/cge.12613","journal-title":"Clin Genet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100700","article-title":"Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy","volume":"26","author":"Dutra-Clarke M","year":"2021","unstructured":"Dutra-Clarke M, Tapia D, Curtin E, et al.. Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy. Mol Genet Metab Rep. 2021, 26:100700. 10.1016\/j.ymgmr.2020.100700","journal-title":"Mol Genet Metab Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biom11020271","article-title":"Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions","volume":"11","author":"Kok K","year":"2021","unstructured":"Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JM, Artola M. Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules. 2021, 11:271. 10.3390\/biom11020271","journal-title":"Biomolecules"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/genes15010037","article-title":"Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations","volume":"15","author":"Izhar R","year":"2023","unstructured":"Izhar R, Borriello M, La Russa A, et al.. Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations. Genes (Basel). 2023, 15:37. 10.3390\/genes15010037","journal-title":"Genes (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1440","article-title":"Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations","volume":"140","author":"Larralde M","year":"2004","unstructured":"Larralde M, Boggio P, Amartino H, Chamoles N. Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. Arch Dermatol. 2004, 140:1440-6. 10.1001\/archderm.140.12.1440","journal-title":"Arch Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini GB","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, et al.. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2012, 1822:226-32. 10.1016\/j.bbadis.2011.11.001","journal-title":"Biochim Biophys Acta"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny R","year":"2005","unstructured":"Dobrovolny R, Dvorakova L, Ledvinova J, et al.. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl). 2005, 83:647-54. 10.1007\/s00109-005-0656-2","journal-title":"J Mol Med (Berl)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175689","article-title":"Morphological hallmarks of classical Fabry disease: an ultrastructural study in a large Spanish family","volume":"12","author":"San Mill\u00e1n-Tejado B","year":"2023","unstructured":"San Mill\u00e1n-Tejado B, Navarro C, Fern\u00e1ndez-Mart\u00edn J, Rivera A, Vi\u00e9itez I, Teijeira S, Ortolano S. Morphological hallmarks of classical Fabry disease: an ultrastructural study in a large Spanish family. J Clin Med. 2023, 12:10.3390\/jcm12175689","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30533","article-title":"Recurrence of Fabry disease as a result of paternal germline mosaicism for alpha-galactosidase a gene mutation","volume":"134A","author":"Dobrovoln\u00fd R","year":"2005","unstructured":"Dobrovoln\u00fd R, Dvor\u00e1kov\u00e1 L, Ledvinov\u00e1 J, et al.. Recurrence of Fabry disease as a result of paternal germline mosaicism for alpha-galactosidase a gene mutation. Am J Med Genet A. 2005, 134A:84-7. 10.1002\/ajmg.a.30533","journal-title":"Am J Med Genet A"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"Schiffmann R","year":"2006","unstructured":"Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2006, 448:337-43. 10.1007\/s00428-005-0089-x","journal-title":"Virchows Arch"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/2141-9248.183935","article-title":"Fabry's disease: case series and review of literature","volume":"6","author":"Wani MM","year":"2016","unstructured":"Wani MM, Khan I, Bhat RA, Ahmad M. Fabry's disease: case series and review of literature. Ann Med Health Sci Res. 2016, 6:193-7. 10.4103\/2141-9248.183935","journal-title":"Ann Med Health Sci Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000345465","article-title":"Possible pathogenetic relationship between Fabry disease and renal cell carcinoma","volume":"36","author":"Pagni F","year":"2012","unstructured":"Pagni F, Pieruzzi F, Zannella S, et al.. Possible pathogenetic relationship between Fabry disease and renal cell carcinoma. Am J Nephrol. 2012, 36:537-41. 10.1159\/000345465","journal-title":"Am J Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o MD","year":"2011","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Carrasco S, et al.. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011, 26:1797-802. 10.1093\/ndt\/gfq306","journal-title":"Nephrol Dial Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453238-fabry-disease-diagnosed-with-lung-nodule-a-unique-presentation-in-a-young-female-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T19:54:58Z","timestamp":1784490898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453238-fabry-disease-diagnosed-with-lung-nodule-a-unique-presentation-in-a-young-female-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.112962","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}